At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12
In Brief
A Phase 2 clinical trial evaluating Atomoxetine and Placebo for Neurogenic Orthostatic Hypotension. Completed, enrolled 48 participants across 2 sites.
Detailed Summary
Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic hypotension are scarce and not effective. If left untreated, these patients have the highest risk of syncope, falls and fall-related injuries. The proposed study will determine the clinical benefit of a commercially available drug, atomoxetine, to reduce symptoms associated with neurogenic orthostatic hypotension in patients with autonomic failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurogenic Orthostatic Hypotension
CountriesUnited States
CollaboratorsNYU Langone Health
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartAug 2016
Primary CompletionMay 2021
Study CompletionJun 2023
TodayJul 2026
First PostedMay 27, 2016
Enrollment StartAug 29, 2016
Primary CompletionMay 12, 2021
Study CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.1 years ago
Interventions
Atomoxetinedrug
norepinephrine transporter inhibitor
Placebodrug
placebo